Newron Pharmaceuticals S.p.A.
Newron Pharmaceuticals S.p.A., a biopharmaceutical company, discovers and develops novel therapies for patients with diseases of the central and peripheral nervous system in Italy and the United States. It offers Xadago (safinamide), a chemical entity for the treatment of Parkinson's in the European Union, the United Kingdom, the United States, Latin America, Switzerland, and Japan. The company's… Read more
Newron Pharmaceuticals S.p.A. (0QOI) - Total Assets
Latest total assets as of June 2025: £61.39 Million GBP
Based on the latest financial reports, Newron Pharmaceuticals S.p.A. (0QOI) holds total assets worth £61.39 Million GBP as of June 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Newron Pharmaceuticals S.p.A. - Total Assets Trend (2005–2024)
This chart illustrates how Newron Pharmaceuticals S.p.A.’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Newron Pharmaceuticals S.p.A. - Asset Composition Analysis
Current Asset Composition (December 2024)
Newron Pharmaceuticals S.p.A.'s total assets of £61.39 Million consist of 95.6% current assets and 4.4% non-current assets.
| Asset Category | Amount (GBP) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | £0.00 | 10.9% |
| Accounts Receivable | £42.42 Million | 66.4% |
| Inventory | £0.00 | 0.0% |
| Property, Plant & Equipment | £0.00 | 0.0% |
| Intangible Assets | £0.00 | 0.0% |
| Goodwill | £0.00 | 0.0% |
Asset Composition Trend (2005–2024)
This chart illustrates how Newron Pharmaceuticals S.p.A.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Newron Pharmaceuticals S.p.A.'s current assets represent 95.6% of total assets in 2024, an increase from 90.6% in 2005.
- Cash Position: Cash and equivalents constituted 10.9% of total assets in 2024, down from 74.3% in 2005.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2005.
- Asset Diversification: The largest asset category is accounts receivable at 66.4% of total assets.
Newron Pharmaceuticals S.p.A. Competitors by Total Assets
Key competitors of Newron Pharmaceuticals S.p.A. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
| No similar companies found. | ||
Newron Pharmaceuticals S.p.A. - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Strong asset utilization - Newron Pharmaceuticals S.p.A. generates 0.80x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Excellent ROA - For every $100 in assets, Newron Pharmaceuticals S.p.A. generates $ 24.79 in net profit.
Newron Pharmaceuticals S.p.A. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.51 | 3.73 | 9.39 |
| Quick Ratio | 1.51 | 3.73 | 9.39 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | £20.39 Million | £ 14.70 Million | £ 38.92 Million |
Newron Pharmaceuticals S.p.A. - Advanced Valuation Insights
This section examines the relationship between Newron Pharmaceuticals S.p.A.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | - |
| Latest Market Cap to Assets Ratio | 4.63 |
| Asset Growth Rate (YoY) | 147.1% |
| Total Assets | £63.91 Million |
| Market Capitalization | $295.80 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Newron Pharmaceuticals S.p.A.'s assets at a significant premium ( 4.63x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Newron Pharmaceuticals S.p.A.'s assets grew by 147.1% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Newron Pharmaceuticals S.p.A. (2005–2024)
The table below shows the annual total assets of Newron Pharmaceuticals S.p.A. from 2005 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | £63.91 Million | +147.07% |
| 2023-12-31 | £25.87 Million | -30.46% |
| 2022-12-31 | £37.20 Million | -26.33% |
| 2021-12-31 | £50.49 Million | -1.39% |
| 2020-12-31 | £51.20 Million | -15.08% |
| 2019-12-31 | £60.29 Million | +0.48% |
| 2018-12-31 | £60.00 Million | -17.84% |
| 2017-12-31 | £73.02 Million | +29.04% |
| 2016-12-31 | £56.59 Million | +27.51% |
| 2015-12-31 | £44.38 Million | +19.71% |
| 2014-12-31 | £37.07 Million | +17.26% |
| 2013-12-31 | £31.62 Million | -29.18% |
| 2012-12-31 | £44.65 Million | +229.11% |
| 2011-12-31 | £13.57 Million | -29.09% |
| 2010-12-31 | £19.13 Million | -54.10% |
| 2009-12-31 | £41.68 Million | -31.16% |
| 2008-12-31 | £60.54 Million | -13.97% |
| 2007-12-31 | £70.37 Million | -18.33% |
| 2006-12-31 | £86.16 Million | +266.67% |
| 2005-12-31 | £23.50 Million | -- |